Selective therapies aiming at restoring p53 pathway to overcome the p53 loss in cancer cells, but not in normal cells, appear to be an attractive strategy for diseases such as chemotherapy-resistant pancreatic cancer. This evidence concerns the gene TP53 and cancer.